Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists
US10881660B2 · kind B2 · utility
9Cited by
8References
23Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 24, 2019 |
| Grant date | Jan 5, 2021 |
| Priority date | — |
| Expiry date | Jan 24, 2039 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P1/16
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides treatment of fatty liver disease using a class of pyrimidinedione cyclohexyl compounds.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.